EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Routine use of a spike‐in DNA in‐process control for foetal RHD genotyping: Testing the real‐world effectiveness of this ‘canary’

Renske M van 't Oever iD, Heleen Woortmeijer, Ahmad Javadi, Aicha Ait Soussan, Barbera Veldhuisen, Claudia C Folman, C Ellen van der Schoot, Erik H van Beers iD, Masja de Haas iD

Vox Sanguinis · 2026

DOI: 10.1111/vox.70188 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vox Sanguinis, 2026. Verfasst von Renske M van 't Oever und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics, Division of Foetal Therapy, Leiden University Medical Center, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Rh-Hr Blood-Group System, Genotyping Techniques, DNA, Cell-Free Nucleic Acids. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives Non‐invasive foetal RHD ( fRHD ) genotyping is widely implemented to prevent unnecessary administration of antenatal anti‐D prophylaxis. Reliable assay performance is critical. In line with expert recommendations, we validated and implemented an artificial spike‐in extraction control in our previously published assay. In this study, we report on assay verification and its performance in a 2‐year cohort. Study Design and Methods fRHD typing was performed with cell‐free DNA isolated from maternal plasma from gestational age week 27 or later. A circular plasmid with a fragment of glycoprotein B gene of the Phocid herpes virus type 1 (PhHV1‐gB) (spike‐in control) was added to the plasma before DNA extraction. Assay accuracy was verified with gestational week‐27 plasma samples and corresponding cord blood samples from D‐negative pregnant women. In addition, assay performance over time was evaluated in a 2‐year cohort.

Results

The performance verification of our modified assay showed no false negative and one false positive test result in a small clinical cohort ( n = 191). In a further 47,391 samples across 1111 runs, we observed eight false negative results due to technical failures that were prevented by the addition of the spike‐in control. In this larger series, the spike‐in control was the sole detector of a technical problem most likely related to different batches of the DNA extraction kit.

Conclusion

This study demonstrates the prevention of false negative fRHD typing results by the addition of an artificial extraction control. This control allows improved monitoring of assay performance, thereby ensuring assay consistency. Findings underscore the importance of thorough quality assurance measures in fRHD genotyping.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rh-Hr Blood-Group SystemGenotyping TechniquesDNACell-Free Nucleic AcidsHumansFemalePregnancyGenotypeFetus

Stichwörter der Autor:innen

cell‐free foetal DNAgenotypingspike‐in control

Substanzen

Rh-Hr Blood-Group SystemDNARho(D) antigenCell-Free Nucleic Acids

Autor:innen und Institutionen

  • Department of Obstetrics, Division of Foetal Therapy, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Immunohematology Diagnostics, Sanquin Diagnostic Services, Amsterdam, The Netherlands.
  • Research, Sanquin, Amsterdam and Landsteiner Laboratory, Amsterdam University Medical Center, Amsterdam, The Netherlands.
  • Medical Affairs, Sanquin, Amsterdam, The Netherlands.
  • Department of Haematology, Leiden University Medical Center, Leiden, The Netherlands.

ORCID-Profile: Renske M van 't Oever, Erik H van Beers, Masja de Haas

Zitieren

APA

van 't Oever, R. M., Woortmeijer, H., Javadi, A., Soussan, A. A., Veldhuisen, B., Folman, C. C., van der Schoot, C. E., van Beers, E. H., & de Haas, M. (2026). Routine use of a spike‐in DNA in‐process control for foetal RHD genotyping: Testing the real‐world effectiveness of this ‘canary’. Vox Sanguinis. https://doi.org/10.1111/vox.70188

Vancouver

van 't Oever RM, Woortmeijer H, Javadi A, Soussan AA, Veldhuisen B, Folman CC, et al. Routine use of a spike‐in DNA in‐process control for foetal RHD genotyping: Testing the real‐world effectiveness of this ‘canary’. Vox Sanguinis. 2026. doi:10.1111/vox.70188

BibTeX
@article{vantOever2026,
  author = {van 't Oever, Renske M and Woortmeijer, Heleen and Javadi, Ahmad and Soussan, Aicha Ait and Veldhuisen, Barbera and Folman, Claudia C and van der Schoot, C Ellen and van Beers, Erik H and de Haas, Masja},
  title = {Routine use of a spike‐in DNA in‐process control for foetal RHD genotyping: Testing the real‐world effectiveness of this ‘canary’},
  journal = {Vox Sanguinis},
  year = {2026},
  doi = {10.1111/vox.70188}
}
Kostenlos starten →